Top NYC, NY Health Tech Companies With Best Stability & Growth (862)

Profitability: Profitability is described as sustained since 2023 while the company continues to scale, pointing to durable unit economics. Company updates also indicate cash‑flow positivity and that efficiency targets such as the Rule of 40 have been surpassed.

Strong Revenue Growth: Revenue growth is characterized as strong over multiple years with momentum continuing into 2026. Acceleration is described alongside expansion in provider supply and booking channels.

Strategic Partnerships: New distribution and integrations, including embedded real‑time booking on Yelp and a payer partnership, broaden patient access points and reinforce growth. These partnerships extend reach beyond the core site into high‑traffic consumer and member channels.

Investor Backing & Capital Strength: Capital raises and valuation step‑ups are prominent, including a $100M Series D in July 2024 at a reported $2.3B valuation to fund expansion into Medicare Advantage and Medicaid. Independent coverage and company materials corroborate the round and use of proceeds.

Market Expansion: Nationwide availability (all 50 states + D.C.) and moves into Medicare Advantage (targeted 51 markets by end‑2024) with Medicaid launches planned for 2025 broaden the addressable market. Company updates indicate these government lines are now active in select states.

Strategic Partnerships: Payer connectivity has accelerated from roughly 40 to 70+ plans with preferred‑network status at major carriers, and revenue scales with completed sessions rather than sign‑ups. These relationships underpin growing patient access and utilization.

Investor Backing & Capital Strength: Fresh capital arrived via a $50M April 2026 investment from Boehringer Ingelheim alongside an earlier Series C led by Dassault Systèmes/Medidata, extending resources for commercialization. The concurrent transfer of CT‑155 commercialization/marketing rights signals committed funding tied to revenue‑bearing activities.

Strategic Partnerships: Long‑running collaborations deepened with Boehringer Ingelheim (commercialization rights for CT‑155) and Otsuka (Rejoyn), while Dassault Systèmes/Medidata broadened a technology partnership to support scale‑up. A January 2026 partnership with Ultrahuman expands reach beyond traditional PDT channels.

Product Line Growth: Recent FDA authorizations for CT‑132 (episodic migraine) and Rejoyn (MDD) broaden the platform and advance the company toward launches. These milestones are highlighted as bolstering credibility for future products.

Investor Backing & Capital Strength: Directional listings on Wellfound and job posts cite roughly $16–17M raised and institutional backing, providing resources to scale despite limited public financials. Portfolio mentions and investor affiliations in multiple sources indicate accessible capital for early growth.

Strong Hiring & Retention: Active hiring signals on Wellfound and LinkedIn, a live careers page, and a stated 11–50 headcount point to ongoing team expansion. Roles across engineering, marketing, operations, and product suggest investment in scaling both product development and go‑to‑market.

Strategic Partnerships: A newly announced partnership with StretchDollar expands distribution into employer benefits channels and was published by both companies. This B2B2C path complements the direct‑to‑consumer motion and can broaden reach beyond individual users.

Investor Backing & Capital Strength: Significant 2025 funding—$35M Series A in March and $100M Series B in September—was explicitly framed to scale teams, deployments, and AI capabilities, with the Series B described as the largest technology raise in senior living at the time. These funds are presented as providing runway to expand nationwide and accelerate product development.

Product Line Growth: The offering broadened in 2025 with the launch of a unified senior‑living ecosystem, adding an emergency call system and later Inspiren HQ with the Inspiren Intelligence analytics engine. This positions the platform as an integrated suite spanning resident safety, care planning, staffing, and emergency response.

Market Expansion: Operator deployments and partnerships (e.g., Arrow Senior Living’s 27 communities, Solera portfolio outcomes, and integrations like August Health) signal expanding footprint and workflow fit in senior living. Dated milestones across 2025–2026 reference a more than doubled customer base and a “year of record growth,” consistent with scaling activity.

Product Line Growth: The launch of a dedicated Platform & Products unit and expansions of the ZAIDYN platform (including new agentic‑AI suites) indicate a deliberate shift toward scalable, productized offerings. These moves suggest expanding monetization levers beyond traditional consulting.

Market Expansion: Headcount and office count have risen, with a global footprint now spanning 40+ locations and new capacity in Hyderabad and Chicago. Inorganic moves such as the acquisition of Salesforce specialist Torrent Consulting extend reach in key healthcare cloud markets.

Strong Market Position & Advantage: Consistent Leader placements by Everest Group and IDC across life‑sciences and analytics services point to competitive strength in core domains. This positioning aligns with indications of healthy demand for ZS’s specialized offerings.

Strong Hiring & Retention: Active recruiting is evident with 20+ open roles on Indeed across multiple states and functions, alongside a LinkedIn size band of 51–200 and recent activity signaling team buildout. Role postings span therapists, a remote RN health advocate, and operations/partnerships positions, indicating capacity expansion.

Market Expansion: Medicare-covered virtual therapy is marketed across all 50 states with state-by-state pages and booking via channels like Zocdoc, pointing to an enlarging go-to-market footprint. Site and blog updates through 2025–2026 and a market-launch role (e.g., Philadelphia) further support ongoing geographic growth.

Strategic Partnerships: A publicly announced collaboration with Advanced Nursing & Home Care and recent LinkedIn partnership/event posts suggest growing referral networks. These signals align with efforts to embed within senior-care ecosystems to broaden distribution.

Investor Backing & Capital Strength: Recent late-stage financings — a February 2026 Series D followed by a May 2026 Series E at a higher stated valuation — indicate strong capital access and confidence. Disclosures cite prominent investors and a sizable valuation step‑up, providing resources to scale.

Market Expansion: Company communications describe reach to almost 800 employer clients and multi‑million member coverage, signaling a broader commercial footprint across the employer market. New feature releases such as Predictive Outreach and added distribution channels support this expanding reach.

Strategic Partnerships: Collaborations announced in 2026 with Priority Health and Atlantic Health extend distribution to commercial employer groups through plan and health‑system channels. These partnerships reinforce access to steer members toward higher‑performing providers.

Investor Backing & Capital Strength: Capital raised is described as substantial, with a $372M Series D in June 2024 led by a16z and participation from Sanofi, explicitly earmarked to grow the pipeline and AI platform. References to $600M+ in total funding and ongoing hiring point to a reinforced capital base supporting expansion.

Strategic Partnerships: Collaborations with Sanofi and OpenAI are presented as first-in-class efforts to apply AI across drug development, signaling external validation and increased resourcing. A 2025 Sanofi licensing deal worth up to €545M further indicates the capability to progress and transact assets with blue‑chip partners.

Product Line Growth: Pipeline activity is shown to be broadening via in‑licensing (e.g., a CNS‑penetrant TYK2 inhibitor in Dec 2025) and movement into the clinic, including first‑in‑human dosing on June 9, 2026. Together, these moves suggest more programs are entering and advancing through clinical stages.

Strong Revenue Growth: Revenue momentum is described as surpassing $200M in annual recurring revenue with sustained hypergrowth over five years as of mid-2026. These disclosures are presented alongside press coverage as the clearest signal of rapid expansion.

Investor Backing & Capital Strength: Capital scale is underscored by a $250M Series E led by Andreessen Horowitz in 2025 and sizeable total funding, paired with a multibillion-dollar valuation cited in coverage. This late-stage financing is tied to expansion plans in healthcare and housing as well as hiring and office growth.

Strong Market Position & Advantage: Adoption signals point to broad penetration in U.S. multifamily, including widespread use among large operators and a meaningful share of apartments nationwide. High-visibility distribution and portfolio rollouts reinforce a defensible position in its core market.

Investor Backing & Capital Strength: Recent funding activity—including a reported portion of a $30M+ round in July 2026 alongside a $28.1M Series B in 2023—signals strengthened runway to support operations and selective scaling. This momentum points to renewed capacity to invest in growth after a difficult 2025.

Market Expansion: A multi-state footprint with launches and active operations across Florida, Michigan, Ohio, Virginia, and Washington reflects continued geographic reach. Active job postings and partner-facing materials further indicate ongoing expansion activity aimed at Medicaid/Medicare populations with SMI.

Strategic Partnerships: Payer-facing positioning and reported collaborations with large platforms (e.g., Carelon Behavioral Health) show ongoing engagement with Medicaid managed care organizations. These arrangements suggest continued commercial traction in value-based models for SMI populations.

Investor Backing & Capital Strength: Capital raised includes a $35M Series A (2024), $70M Series B (2025), and $100M Series C (2026), with reports of a roughly $1.75B valuation. Consistent step-ups in round size and total funding signal traction and confidence to fuel scale.

Profitability: Profitability is reported for 2025, unusual among digital health peers at this stage. This indicates operating leverage with payer reimbursement working as intended.

Strategic Partnerships: Payer coverage spans national commercial plans plus Medicare and Medicaid, a key lever for patient acquisition and revenue consistency in virtual care. Broad distribution is reflected in nationwide availability and hundreds of thousands of patients served.

Product Line Growth: New AI capabilities under Cedar Intelligence and an agentic voice product that has already handled a large volume of billing calls point to an expanding offering across personalization, voice support, and affordability workflows. Recent launches such as coverage and support modules broaden the platform beyond core payments.

Market Expansion: Selection by marquee providers and payer–provider deployments, alongside publicly cited scale in patient journeys and payment volumes, indicate wider adoption and usage across the ecosystem. Added channel traction with ambulatory practices and entry into adjacent areas like dental further extend reach.

Strategic Partnerships: Collaborations with major payers and technology platforms bolster distribution and product capability, exemplified by joint deployments and communications/cloud integrations. These relationships reinforce differentiation around unifying payer–provider financial workflows.

Strong Revenue Growth: Public disclosures indicate revenue surpassed $1B in 2023 and remained above that level in 2024–2025, with 2024 noted at roughly $1.1B. These signals point to ongoing top‑line expansion.

Product Line Growth: Recent launches and releases such as IntelliCare and the 2026.1 updates for IRIS, IRIS for Health, and Health Connect highlight an active roadmap. This cadence is presented as expanding the addressable market and creating new upsell paths.

Strong Market Position & Advantage: Industry recognition places the company as a Leader in the 2026 Gartner Magic Quadrant for Enterprise EHRs and the 2025–2026 IDC MarketScape for analytical databases, alongside multiple 2026 Best in KLAS #1 rankings. These placements signal competitive strength and buyer traction in core markets.

Strong Revenue Growth: Revenue is reported at about $1.27B for 2025 (~80–83% YoY), with Q4 2025 at $367.2M (+83% YoY) and Q1 2026 at $348.1M (+36% YoY); full‑year 2026 is guided to $1.59–$1.60B (~25% growth). Segment data show Diagnostics up 34.7% and Data & Applications up 40.5% YoY in Q1 2026.

Strategic Partnerships: Record total contract value exceeding $1.1B and multi‑year collaborations with AstraZeneca, Merck, Gilead, and Bristol Myers Squibb are highlighted. These arrangements support growth in data/software lines and add forward revenue visibility.

Product Line Growth: MRD testing reached ~6,500 in Q1 2026 (up ~500% YoY), and acquisitions of Ambry Genetics, Paige.AI, and Deep 6 AI broaden testing and AI capabilities. Management points to horizontal integration and cross‑selling (e.g., with Ambry) as contributors to expected growth.

Strong Revenue Growth: Repeated inclusion on the Inc. 5000 list in 2024 and 2025 indicates multi‑year revenue expansion. This sustained recognition points to continued top‑line momentum through mid‑2026.

Innovation-Driven Growth: Recent AI launches for ABA operations (e.g., an AI dashboard and AI‑assisted documentation) reflect active product investment. This cadence suggests a focus on differentiation and upsell potential across the platform.

Market Expansion: Expansion via acquisition—most notably the August 2025 purchase of Joshin—positions the portfolio to cover broader neurodiversity and disability support. Partnerships and integrations alongside broad employer, education, and provider adoption indicate a scaling footprint.

Strong Revenue Growth: Total revenue grew 23% year over year to $255.9M in 2025, with software up 10.6% and drug discovery more than doubling to $56.4M. Guidance for 2026 points to 10–15% software ACV growth, and Q1 2026 ACV rose 12% year over year.

Strategic Partnerships: Royalty‑eligible collaborative programs increased to 16 by year‑end 2025, with multiple partner milestones (e.g., Takeda’s TYK2 from Nimbus, Structure Therapeutics updates) and integrations like Lilly’s TuneLab in LiveDesign signaling ecosystem momentum. These relationships can generate milestones and potential royalties that support future growth.

Investor Backing & Capital Strength: Cash and marketable securities were about $402M at year‑end 2025 (approximately $406M at Q1 2026), and operating expenses are guided below 2025 levels for 2026. This liquidity and cost discipline provide runway to advance the hosted transition and the discovery portfolio.

Strong Market Position & Advantage: PatientPoint is described as the nation’s largest digital point‑of‑care network, citing roughly 30,000–35,000 physician offices and about 145,000 screens, signaling outsized scale. Expanded Media Rating Council accreditation in April 2026 across its full screen network can further strengthen advertiser confidence and budgets.

Product Line Growth: In 2026 the company launched programmatic buying via PatientPoint Health Audiences and introduced a Consumer Health Network for CPG/OTC brands, broadening monetization avenues. These moves are positioned to expand the addressable revenue beyond traditional pharma channels.

Investor Backing & Capital Strength: Advent International signed a definitive agreement to acquire PatientPoint in August 2025, framed as a catalyst to accelerate network expansion and product innovation. Such backing is presented as a strong vote of confidence in both the company and the point‑of‑care media category.

Innovation-Driven Growth: AI site selection and AI patient pre-screening launched in 2025–2026 are described as streamlining screening and improving enrollment efficiency. These releases signal a deepening product footprint aligned to faster activation and more representative enrollment.

Strategic Partnerships: A 2025 data partnership with RealTime eClinical Solutions and highlighted work with major pharma logos are presented as ecosystem validation and traction. These collaborations integrate site performance data and extend marketplace reach.

Market Expansion: The network is portrayed as growing from about 5,500 to 6,000+ research sites across 50+ countries into 2026. Sponsor materials and industry posts indicate steady expansion of marketplace breadth.

Product Line Growth: Launched and acquired products are scaling, with oncology assets from the Seagen deal and brands such as Padcev, oncology biosimilars, Nurtec, Lorbrena, Abrysvo, Eliquis, and the Vyndaqel family cited as key contributors. Early‑2026 updates describe a meaningful uptick from these newer and in‑line medicines.

Innovation-Driven Growth: Management highlights a robust late‑stage pipeline with numerous pivotal study starts planned in 2026 and catalysts across oncology, vaccines, and metabolic disease. Programs such as an ADC (sigvotatug vedotin) and a GLP‑1 RA (berobenatide) are positioned to convert into future approvals and launches.

Diversified Revenue Streams: Growth beneath the surface is coming from multiple non‑COVID franchises rather than a single product, spanning oncology (including Seagen’s ADCs), vaccines, neurology, and cardiovascular. This breadth is helping to offset normalization in COVID‑related sales.